Trilogy-4
79635322MMY3001

Phase III

A Phase 3 Randomized Study Comparing JNJ-79635322 and an anti-BCMA AxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma who Have Received at least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody

EU-CT-Nummer: 2025-522007-18

CO46577
CevoGeMM

Phase II

Cevostamab in Combination With Pomalidomide and Dexamethasone after BCMA-Targeting CAR T-Cell Therapy in Patients With Previously Treated Multiple Myeloma

Eudract Nr. 2026-525736-42